Torii Calls Off PII Study of Menlo’s Pruritus Candidate

Torii Pharmaceutical has terminated a Japanese PII clinical trial of serlopitant, coded JTS-661, an oral pruritus drug candidate licensed from US biotech Menlo Therapeutics, the company revealed on April 26. Serlopitant has been codeveloped by Torii and its parent company...read more